Ascendis Pharma A (ASND) EBT Margin (2014 - 2026)
Ascendis Pharma A (ASND) reported EBT Margin of 19.54% for Q1 2026, up 7314.0% on a YoY basis from 0.26% in Q1 2025, and down 204.66% sequentially from 6.41% in Q4 2025.
Ascendis Pharma A (ASND) EBT Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A (ASND) has 13 years of EBT Margin data on file, last reported at 19.54% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 7314.0% year-over-year to 19.54%; the trailing twelve-month figure through Mar 2026 stood at 16.15% (up 5124.0% YoY), and the FY2025 full-year result was 29.53%, up 6245.0% from the prior year.
- EBT Margin fell to 19.54% in Q1 2026, from 6.41% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 6.41% in Q4 2025 to a low of 1834.46% in Q1 2022.
- A 5-year average of 404.55% and a median of 169.76% in 2024 frame the typical range for EBT Margin.
- Peak annual rise in EBT Margin reached 1183392 bps in 2022, while the deepest fall reached 75932 bps in 2022.
- Tracing ASND's EBT Margin over 5 years: stood at 882.6% in 2022, then soared by 97 bps to 26.79% in 2023, then soared by 55 bps to 12.06% in 2024, then jumped by 47 bps to 6.41% in 2025, then slumped by 205 bps to 19.54% in 2026.
- Business Quant data shows ASND's EBT Margin at 19.54% in Q1 2026, 6.41% in Q4 2025, and 26.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Ascendis Pharma A | 15.35 Bn | 14.68 Bn | 268.20 Mn | -19.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.54% |
| Dec 31, 2025 | -6.41% |
| Sep 30, 2025 | -26.86% |
| Jun 30, 2025 | -22.15% |
| Mar 31, 2025 | -92.68% |
| Dec 31, 2024 | -12.06% |
| Sep 30, 2024 | -169.76% |
| Jun 30, 2024 | -303.21% |
| Mar 31, 2024 | -134.03% |
| Dec 31, 2023 | -26.79% |
| Sep 30, 2023 | -336.38% |
| Jun 30, 2023 | -257.13% |
| Mar 31, 2023 | -326.35% |
| Dec 31, 2022 | -882.60% |
| Sep 30, 2022 | -1,106.10% |
| Jun 30, 2022 | -1,320.88% |
| Mar 31, 2022 | -1,834.46% |
| Dec 31, 2021 | -123.27% |
| Sep 30, 2021 | -7,218.60% |
| Jun 30, 2021 | -13,154.79% |